These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33823169)

  • 61. The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization.
    Chen SH; Yang SH; Chu SC; Su YC; Chang CY; Chiu YW; Kao RH; Li DK; Yang KL; Wang TF
    Int J Hematol; 2011 May; 93(5):652-659. PubMed ID: 21509437
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors.
    Ordemann R; Hölig K; Wagner K; Rautenberg U; Bornhäuser M; Kroschinsky F; Schäfer J; Schuler U; Ehninger G
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S25-8. PubMed ID: 9712488
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The effect of repeated stimulated granulocyte donations on hematopoietic indexes in donors: a 24-year donor center experience.
    Szymanski J; Troendle J; Leitman S; Hong H; Yau YY; Cantilena C
    Transfusion; 2019 Jan; 59(1):259-266. PubMed ID: 30444537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
    Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
    Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells.
    Bolan CD; Carter CS; Wesley RA; Yau YY; Barrett AJ; Childs RW; Read EJ; Leitman SF
    Br J Haematol; 2003 Mar; 120(5):801-7. PubMed ID: 12614213
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blood stem cell procurement: donor safety issues.
    Anderlini P; Przepiorka D; Körbling M; Champlin R
    Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S35-9. PubMed ID: 9712491
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
    Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peripheral blood as a stem cell source for hematopoietic cell transplantation in children: is the effort in vein?
    Lipton JM
    Pediatr Transplant; 2003; 7 Suppl 3():65-70. PubMed ID: 12603696
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Allogeneic blood stem cell transplantation: considerations for donors.
    Anderlini P; Körbling M; Dale D; Gratwohl A; Schmitz N; Stroncek D; Howe C; Leitman S; Horowitz M; Gluckman E; Rowley S; Przepiorka D; Champlin R
    Blood; 1997 Aug; 90(3):903-8. PubMed ID: 9242518
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.
    Pahnke S; Larfors G; Axdorph-Nygell U; Fischer-Nielsen A; Haastrup E; Heldal D; Itälä-Remes M; Johansson JE; Kauppila M; Lenhoff S; Ljungman P; Niittyvuopio R; Sandstedt A; Hägglund H
    J Clin Apher; 2018 Jun; 33(3):226-235. PubMed ID: 28833474
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center.
    Bailén R; Pérez-Corral AM; Pascual C; Kwon M; Serrano D; Gayoso J; Balsalobre P; Muñoz C; Díez-Martín JL; Anguita J
    J Clin Apher; 2019 Aug; 34(4):373-380. PubMed ID: 30694583
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34
    Martino M; Gori M; Moscato T; Naso V; Ferreri A; Provenzano F; Loteta B; Sanguedolce MC; Console G; Dattola A; Pucci G; Gentile M; Morabito A; Recchia AG; Tripepi G; Pitino A
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1586-1591. PubMed ID: 31002994
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of short G-CSF administration on the numbers and clonogenic efficiency of hematopoietic progenitor cells in bone marrow and peripheral blood of normal donors.
    Zaucha JM; Knopińska-Posłuszny W; Bieniaszewska M; Myśliwski A; Hellmann A
    Ann Transplant; 2000; 5(4):20-6. PubMed ID: 11499355
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unusual adverse events following peripheral blood stem cell (PBSC) mobilisation using granulocyte colony stimulating factor (G-CSF) in healthy donors.
    Hilbe W; Nussbaumer W; Bonatti H; Thaler J; Niederwieser D; Nachbaur D
    Bone Marrow Transplant; 2000 Oct; 26(7):811-3. PubMed ID: 11042668
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in beta-thalassemia patients: kinetics of mobilization and composition of apheresis product.
    Li K; Wong A; Li CK; Shing MM; Chik KW; Tsang KS; Lai H; Leung TF; Yuen PM
    Exp Hematol; 1999 Mar; 27(3):526-32. PubMed ID: 10089916
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of the efficacy of peripheral blood stem cell mobilization using G-CSF alone from healthy donors and patients with hematologic malignancies.
    Kawamura K; Kikuchi M; Terasako K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Kimura S; Nakasone H; Okuda S; Yamazaki R; Kanda J; Kako S; Tanaka Y; Tanihara A; Nishida J; Kanda Y
    Transfus Apher Sci; 2013 Oct; 49(2):334-40. PubMed ID: 23810219
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting.
    Bredeson C; Leger C; Couban S; Simpson D; Huebsch L; Walker I; Shore T; Howson-Jan K; Panzarella T; Messner H; Barnett M; Lipton J
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):405-14. PubMed ID: 15148494
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency.
    Tichelli A; Passweg J; Hoffmann T; Gregor M; Kühne T; Favre G; Wodnar-Filipowicz A; Gratwohl A
    Br J Haematol; 1999 Jul; 106(1):152-8. PubMed ID: 10444178
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.